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Abstract
Vaccinia virus (VACV) is well known for its use as the vaccine in the
successful campaign to eradicate smallpox and a powerful vector for vaccines,
immunotherapies, and oncolytic viral therapies. Advancements in synthetic
biology have recently led to the development of synthetic gene circuits, which
can use recombinases to respond to inputs with logic and memory. We propose
that this technology can be employed to make “logical” VACV vectors which
could be programmed to change their actions based on sensory inputs for use in
the development of safer vaccines or oncolytic viral therapy agents which
selectively lyse cancer cells. In this project we tested the functionality of
recombinases Bxb1 and PhiC31 in synthetic VACV circuitry. We developed
simple synthetic circuits with VACV promoters wherein each recombinase can be
induced under lac or tet operon elements to irreversibly invert a promoter, which
switches fluorescent reporter expression from red to green and can be observed
in VACV infection/transfection assays. We detected only red fluorescence with
little to no green in cells transfected with bxb1 plasmids, suggesting that no
promoter inversion occurred and Bxb1 may not be functional in VACV-infected
cells. Green fluorescence indicative of promoter inversion was detected in all
cells transfected with phiC31 plasmids. This occurred regardless of absence of
inducer, suggesting PhiC31 is highly functional in VACV-infected cells but cannot
be regulated by TetR or LacI repressor proteins, even when they are preexpressed at high levels. Future recombinase-based synthetic circuitry in VACV
will thus require tighter repressor systems.
vi

INTRODUCTION

Vaccinia Virus Overview
Vaccinia virus (VACV) is a large, enveloped, double-stranded DNA virus
prototypical of the family Poxviridae and the genus Orthopoxvirus. The VACV
infectious cycle begins with attachment and entry of a virion into a susceptible
cell. Entry occurs by fusion of the viral lipid membrane to the cell membrane,
releasing the core into the cytoplasm (1), where replication occurs (2).
Transcription is divided into early, intermediate, and late stages. Early
transcription is coupled to the replication of the viral genome (3), which once
completed proceeds to intermediate and late stages when genes for the
synthesis of proteins for new viral particles are transcribed (4). Transmission of
VACV between cells can take place by spread of intracellular mature virus after
cell lysis, movement of cell-associated enveloped virus on actin tails to adjacent
cells, and by extracellular enveloped virus traveling to proximate or distant cells
(5).

Applications of Recombinant Vaccinia Virus Vectors
VACV was employed as the vaccine in the World Health Organization
campaign to eradicate smallpox (6). As a result, the scientific community has
extensive understanding of VACV. The VACV genome can accommodate over
25 kilobases (kb) of exogenous DNA (7), and such “recombinant” VACVs are
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excellent expression vectors in eukaryotic cells. Additionally, recombinant VACVs
have been shown to elicit strong humoral and cell-mediated immune responses
both for vaccine and oncolytic therapy applications (8, 9). By expressing
exogenous antigens, a recombinant VACV can train the immune response
against different pathogens. Recombinant VACV vectors have accordingly been
used extensively as both human and animal vaccines (10), including oral rabies
vaccines for wildlife (11-13) and recently, promising HIV vaccines (14, 15). VACV
has also been used for cancer vaccines, eliciting an immune response against
cancers by expressing tumor-associated antigens (16). VACV has also shown
great potential as an agent for oncolytic viral therapies since it can replicate in
many mammalian tissues and destroys tumors both directly by virus-mediated
cytotoxicity and by inciting the host cell-mediated effector immune response (17).
Additionally, it has also been implemented in tumor-directed gene therapies,
wherein viruses are targeted specifically to tumor cells and used to express
enzymes which interact with prodrugs administered to the patient, increasing
cure rate and prolonging survival (18).
The clinical use of these VACV-based therapies is limited by
complications due to uncontrolled viral replication ranging from mild rash and
fever, to rare but severe adverse reactions. These are usually limited to
individuals with pre-existing susceptibilities, such as eczema in the case eczema
vaccinatum and immune deficiency in the case of progressive vaccinia (19). As a
result, many researchers have elected to use replication-deficient or attenuated
VACV strains such as Modified Vaccinia virus Ankara (MVA) (20). However,
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interest in using replication-competent and more immunogenic strains such as
Western Reserve (WR) has prompted the development of regulatory systems for
the situational control of vaccinia gene expression and replication, including
inducible systems using elements of the lac or tet operons, and a repressible
system using a reverse tet repressor (Hagen, Jasperse and Titong, unpublished),
(21-23).

Lac and Tet Operons
The lac operon is the prototypical bacterial gene regulatory unit and its
discovery and characterization are of great historical importance in molecular
biology (24). Originally described by Jacob and Monod, it was the basis for the
understanding of bacterial gene regulation, wherein the protein products regulate
the expression of genes at the level of transcription depending on environmental
conditions (25). In the lac operon, “structural genes” including β-galactosidase
and a lactose transporter are downstream of an operator sequence, to which the
lac repressor protein LacI binds, preventing transcription in the absence of the
metabolite allolactose (26-28). An artificial analog for allolactose developed by
Monod, 1-isopropyl-β-d-thiogalactoside (IPTG), can be used as a gratuitous
inducer of the lac operon (26).
The tet operon was also discovered in Escherichia coli, in which the
expression of TetA, a transporter protein enabling resistance to tetracyclines, is
regulated analogously to the lac operon; repressor protein TetR binds tightly to
the tetO operator sequence in the absence of tetracyclines, preventing
3

expression of tetA, but in the presence of tetracyclines a conformational change
takes place which decreases affinity of TetR for the operator and allows for tetA
transcription (29, 30). This regulatory system has been extensively used as a
transactivator in both prokaryotes and eukaryotes to regulate both endogenous
and transgene expression (31-33). Both the lac and tet repressor systems have
been previously characterized in VACV vectors (22, 34, 35).

Applications of Current Tools in Synthetic Biology
Synthetic biology is a rapidly evolving field that is generally defined as the
design and construction of novel biological systems or the re-design of existing
biological systems to solve problems. In the former category, synthetic biologists
develop artificial biomolecules which parallel known ones in the interest of
creating artificial life, which although popular, exciting, and promising, is not the
aim of our project and will not be discussed here (36). In the latter, scientists
draw on a body of scientific knowledge about components of different biological
systems and integrate them in various degrees of complexity to engineer a
biological design (37). This technology can be used to assemble biological
pathways for the synthesis of industrially important chemicals (38).
Of particular interest to us are synthetic regulatory gene networks. We
believe that if VACVs could be developed with complex artificial regulatory
systems that can interact with their environment, they would have myriad
potential uses in medicine and research. Using well-studied and standardized
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genetic elements, over the past decade and a half synthetic biologists have
developed numerous varieties of genetic circuit elements capable of responding
to environmental inputs. Using a pair of promoters and repressors, Gardner et al.
developed a bistable genetic toggle switch to control gene expression (39).
Transcriptional regulatory systems have also been built to oscillate on a
timescale different from their host organism’s replicative processes, allowing the
state of the synthetic gene circuit to be transmitted and self-maintaining through
generations (40). The implementation of recombinases, enzymes which catalyze
the excision, inversion, and reinsertion of a target DNA sequence (41) in
synthetic biology, or “recombinatorics”, has opened the door to the development
of computer-like logic in synthetic biology (42). At the simplest level, these
recombinases catalyze irreversible inversions and allow for strict regulation of an
inducible expression system (43). It is also possible to use recombinases that
catalyze reversible inversion in conjunction with excisionases to create rewritable
memory systems inside the genetic code of living cells (44). These technologies
have demonstrated usefulness in bacterial and viral vectors with practical
medical applications, including the engineering of bacteria to invade cancer cells
or to destroy biofilms and thus serve as adjuvants for antibiotic therapies (45,
46). An excellent review on the current accomplishments and obstacles in the
field of synthetic gene networks was written by Lu et al (47). Recently, Siuti et al.
used recombinase-based synthetic gene circuitry to implement the sixteen
Boolean logic gates in E. coli using two recombinases under different inducible
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systems to integrate two signals into one logical output with “memory” which
lasted through bacterial generations (48).

Bxb1 and PhiC31 Recombinases
For this project we sought recombinases that could carry out a
unidirectional, irreversible inversion of a DNA segment flanked by recognition
sequences specific to that enzyme, such that if a multi-recombinase logic system
were ever developed, there would be no cross-reactivity between one
recombinase and the recognition sites of another. Bacteriophage large serine
recombinases catalyze viral integration by acting on a specific site on the viral
genome (attP) and another on the host chromosome (attB), but can also catalyze
the inversion of DNA segments resulting in gene expression (49). They do this by
binding the DNA segments, cleaving them, repositioning their ends by subunit
rotation, and ligating the segments together (50). We selected two large serine
recombinases, Bxb1 (51) and PhiC31 (52) for use because they both have been
thoroughly characterized (53), used by genetic engineers in eukaryotes (53-55),
and were used by Siuti et al. in their Boolean logic circuits project (48),
suggesting that there is no cross-reactivity between them and that they can be
expressed as transgenes in eukaryotic cell lines.
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Hypothesis
Recombinase-based synthetic gene circuits stand to greatly increase the
potential uses and safety of VACV vectors. Because the VACV genome can
accommodate 25 kb of exogenous genetic material, recombinant VACV vectors
theoretically could be produced with multiple foreign or natural genes under a
complex multi-recombinase regulatory system. We hypothesize that
recombinase-based gene circuit regulation is possible in VACV. Because VACV
replicates in the cytoplasm using its own transcriptional machinery, it is not
possible to create a recombinant VACV with recombinase logic using existing
synthetic circuitry because at the time of this paper none have included VACV
promoters. The goal of this project was to demonstrate that recombinase-based
regulation in a simple genetic circuit is possible in VACV. In the interest of
ultimately building circuits with binary inputs, we sought to test two
recombinases. We placed them under the control of a weak VACV promoter and
inducible operator so their expression could be controlled by the administration of
inducer molecules doxycycline (Dox) or IPTG. A reporter cassette was generated
with a red and green fluorescence reporter on either side of a strong vaccinia
promoter flanked by recombinase recognition sequences. If repression of
recombinase activity with VACV transcription machinery is sufficient, then only
red fluorescence reporter is produced. Induction of the recombinase results in
inversion of the promoter, cessation of red fluorescence reporter expression and
transcription of green fluorescence reporter (Figure 1).

7

MATERIALS AND METHODS

PCR of Recombinase Genes
Two recombinases (Bxb1 and PhiC31) and their recognition sites (53),
were selected for use in our experiments on the basis of their previous use in
mainstream synthetic biology projects with similar circuitry. phiC31 was obtained
from plasmid “pInt” (56) and bxb1 was obtained from plasmid “DualRecombinase Controller” (57), both from Addgene (Cambridge, MA).
Recombinase genes were PCR-amplified so that the final products would have 5’
and 3’ restriction sites to facilitate cloning into a vector backbone. Forward
primers overlapped with the translation start site and included a 5’ spacer (6 bp)
and restriction enzyme recognition site immediately preceding the start codon.
Reverse primers overlapped with the sequence complementary to the 3’ end of
the gene and included a 5’ spacer (6 bp) and restriction enzyme recognition site
immediately preceding the complement of the stop codon.

Logical Circuit Plasmids
A vector backbone was synthesized to enable subcloning of red
fluorescent reporter DsRed and green fluorescent reporter EGFP, recombinase
bxb1 or phiC31, and repressor gene tetR or lacI. Vector backbones were
synthesized by a third party vendor DNA 2.0 (Menlo Park, CA) as high copy
plasmids with a kanamycin resistance gene. Spacers of 25 bp from ampR were
8

included between restriction enzyme cut sites. Promoters were chosen based on
the desired level of expression for each gene. Because even minimal expression
of a recombinase could result in inversion of our target promoter, we sought to
maximize expression of our repressor genes and have minimal but sufficient
levels of expression of our recombinase when unrepressed. We also selected
promoters with minimal sequence similarity to one another in order to avoid
unwanted recombination events. We chose synthetic promoter PE/L, the strongest
known VACV promoter, for expression of lacI and tetR. The strong cowpox
promoter PATI, as previously modified by the Verardi Lab (23), was selected for
reporter gene expression. P5, a weakened version of late promoter P11 (23) was
chosen to drive recombinase expression. Restriction enzyme sites were selected
based on the availability of genes from plasmids and enzymes in the Verardi Lab
in order to minimize the need for PCR cloning and minimize the use of enzymes
that would cut within the final transfer vector. Vector pPL189 was synthesized
with recombinase recognition sites bxb1 attB/attP for use with bxb1 under control
of the lac operon (Figure 2A). Vector pPL190 was synthesized with recombinase
recognition sites phiC31 attB/attP for use with phiC31 under control of the tet
operon (Figure 2B).
Inserts were cloned into vector backbones in parallel. Unless otherwise
stated, plasmids were obtained from the Verardi Lab and enzymes were obtained
from New England Biolabs (Ipswich, MA). Genes encoding respective repressor
proteins were subcloned into the vector backbones first. The lacI-wf gene is a
W200F mutant lacI that has been shown to produce a repressor with a 10-fold
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greater decrease in leaky transcription (58). Our lab had previously synthesized
lacI-wf with mutation in a TTTTNT to prevent early transcription termination by
VACV transcriptional machinery. For cloning, lacI-wf was cleaved from pCO157
with PstI-HF and blunt cutting restriction enzyme SmaI and cloned into pPL189
cleaved with PstI-HF and blunt cutting restriction enzyme ScaI-HF to create
pPL193. The tetR gene was obtained from pSMART10 because that version of
the gene was also synthesized to lack a VACV terminator sequence TTTTTNT
present in the wild type gene (14). pSMART10 was cleaved with SphI-HF and
SmaI and cloned into pPL190 cut with SphI-HF and ScaI-HF to create pPL192 .
EGFP was cloned into pPL192 and pPL193 from pCO191 with SacI-HF and
NcoI-HF to create pPL194 and pPL195. DsRed was cloned into pPL194 and
pPL195 from pCO191 with SpeI and NotI-HF to create pPL196 and pPL197.
Recombinases were cleaved from their PCR amplicon into pPL196 and pPL197
with MfeI-HF and NotI-HF to create pPL198 and pPL199 for transient expression
assays in VACV-infected cells (Figure 2C-D). To isolate the variables of each
inducible system and recombinase, we then generated two more plasmids; in
pPL200 bxb1 is under control of the tet operon, and in pPL201 phiC31 is under
control of the lac operon. This was accomplished by digesting pPL198 and
pPL199 with MfeI-HF and KpnI-HF and swapping out the inserts and vectors
(Figure 2E-F).
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Gene Cloning
Inserts were double digested from plasmids or PCR amplicons in the case
of the recombinases, and vectors were double digested to remove spacers with
restriction enzymes to create mutually compatible cleavage sites for directional
cloning. Note that in the digestion of pPL198 with MfeI-HF and KpnI-HF, the
insert and vector were of indistinguishable size, so to facilitate gel purification it
was also incubated with NdeI or EagI-HF, digesting the unwanted fragment into
smaller pieces. Vectors were dephosphorylated by incubation with Antarctic
Phosphatase. Inserts and vectors were ligated with T4 DNA ligase and
electroporated with a Gene Pulser Xcell Electroporation System (Bio-Rad,
Hercules, CA) into NEB 5-alpha Electrocompetent E. coli (New England Biolabs),
The electroporated suspension was plated onto low-salt LB agar plates with 50
µg/ml kanamycin and incubated for 16 hours at 37°C. Twenty well-isolated
colonies were miniprepped and the DNA was evaluated for desired ligation and
transformation results by diagnostic restriction enzyme digest and
electrophoresis in an agarose gel containing ethidium bromide visualized by
ultraviolet excitation. One culture verified to contain the desired plasmid was
grown for a larger scale DNA isolation and use in subsequent cloning reactions.
DNA isolation and purification was performed using a NucleoSpin® Plasmid kit
(Macherey-Nagel, Bethlehem, PA). pPL198, pPL199, pPL200, and pPL201 were
grown up, isolated, and purified on a larger scale using a NucleoSpin® Midiprep
kit (Macherey-Nagel). After large scale-preparation with a commercial kit,
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plasmids were reanalyzed with a restriction-enzyme digest and compared with
the original vector to verify the identity of the product.

Cell Culture
African Green Monkey kidney epithelial cells (BS-C-1) and human HeLaS3 cells were grown in adherent culture with Dulbecco’s modified Eagle medium
supplemented with glucose and amino acids (Invitrogen, Grand Island, NY)
(cDME) and containing 10% fetal bovine serum (FBS; Atlanta Biologicals,
Lawrenceville, GA) at 37 °C in 5% CO2 as described previously (22).

Viruses
L-variant Western Reserve (WR) VACV ATCC clone 9.2.4.8. (22) was
used as our wild-type VACV strain and was previously amplified in HeLa-S3
cells, purified, and titered in BS-C-1 cells by the Verardi Lab. vP11IRG was
previously developed, purified and amplified by our lab (Titong, Jasperse, Verardi
unpublished data). It was generated by homologous recombination of plasmid
pSP114 with the VACV thymidine kinase region. It contains tetR under a PE/L
promoter, lacI under P11 and a tet operator, and EGFP under another P11 and a
lac operator; so in the presence of Dox LacI is produced, preventing expression
of EGFP. vS22 is a previously developed VACV (vPE/L-Control) that expresses
tetR constitutively under the PE/L promoter (21).
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Transient Expression Assays
BS-C-1 or HeLa-S3 cells were seeded in 24 or 48-well cell culture plates
to be 95% confluent at the time of the experiment. VACV stocks were sonicated
in four 30-second bursts, vortexed between bursts, and diluted to achieve an
MOI of 1 based on the desired infection volume and estimated number of cells
per well. Cells were washed once with cDME, overlayed with virus dilution, and
incubated for 1 hour post-infection during initial testing and 24 hours for
subsequent testing when we wanted to pre-express LacI and TetR in vS22 and
vP11IRG infected cells. Cells were then overlaid with cDME supplemented with
2.5% FBS +/- 1 mg/ml Dox or 1 mM IPTG and transfected with desired plasmids
using FuGENE HD transfection reagent (Promega, Madison, WI). Cells were
incubated at 37 °C in 5% CO2. Results were obtained by fluorescence (Texas
Red filter for DsRed and FITC filter for EGFP) and brightfield microscopy at 24,
48, and 72 hours post transfection using an Axio Observer D1 inverted
fluorescence microscope (Carl Zeiss, Thornwood, NY). Images were captured
using AxioVision software, release 4.8.1 (Carl Zeiss). Representative images
were taken.
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RESULTS
A pilot transient expression assay was performed in BS-C-1 cells using
pPL198 and pPL199. Cells were infected with WR for one hour prior to
transfection. 48 hours post transfection (p.t.), all wells transfected with pPL198
exhibited green fluorescence at similar levels to the transfection control with no
detectable red fluorescence, which persisted for the course of the experiment.
(Figure 3). Red fluorescence was detected in pPL199-transfected wells (Figure
3A) at levels similar to the transfection control (Figure 3C). After 72 hours, small
amounts of green fluorescence were observed in the pPL199-transfected wells
both with and without IPTG, which otherwise exhibited red fluorescence similar to
transfection control levels (Figure 3B).
During the pilot experiment we observed that at 48 and 72 hours post
infection, data collection became increasingly difficult due to the number of BS-C1 cells that lysed or lost adherence to the plate, so subsequent assays were
performed in HeLa-S3 cells. In order to confirm that the results of the pilot
experiment were not due to improper insertion of fluorescent reporter genes or
promoter inversion prior to transfection, we reanalyzed the placement and
orientation of the recombinases in the plasmids via a different restriction digest
and PCR, confirming our original determination that the plasmids were as
designed.
Next we tested pPL198, pPL199, pPL200, and pPL201 (Figure 2) in HeLaS3 cells infected with WR. To control for the possibility that in the first experiment
PhiC31 was synthesized before sufficient repressor was produced to modulate
14

expression, we also tested tet operator plasmids pPL198 and pPL201 in cells
infected with vS22, a recombinant VACV that constitutively expresses TetR, and
lac operator plasmids pPL199 and pPL200 in cells infected with vP11IRG, a
recombinant VACV that constitutively expresses LacI. Because vP11IRG
expresses EGFP in a tetracycline-repressible fashion, cells infected with it were
overlaid with media containing 1 mg/ml Dox, previously shown to repress EGFP
expression to levels indistinguishable from WR (Titong et al., unpublished data).
Our vP11IRG control (no plasmid transfected) results were consistent with this at
24 hours post infection (Figure 4A), however after 48 (Figure 4B) and 72 hours
(Figure 4C), we noticed a few cells (less than 10 in a well of ~9.4x104 cells) with
green fluorescence, suggesting that this virus may undergo mutation to
constitutive EGFP expression. We also noted after 72 hours a detectable amount
of EGFP fluorescence localized to every cell (Figure 6D), suggesting that a small
amount of expression had occurred. These findings limit the power of our results
from vP11IRG-infected cells.
The HeLa-S3 cells did maintain a better monolayer for fluorescence
imaging than the BS-C-1 cells, even when infected with VACV, but once again
we never observed any difference between groups with or without inducer
(Figure 5). Cells infected with WR and transfected with pPL198 (Figure 5A) or
pPL200 (Figure 5B) exhibited green fluorescence similar to the level of the
transfection control (Figure 5E), with no detectable red fluorescence. This was
also true for cells infected with rVACVs vS22 and vP11IRG to pre-express
repressor proteins TetR and LacI respectively (Figure 5C-D). These data suggest
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that PhiC31 is functional in our VACV synthetic circuitry, but it cannot be
controlled by the lac or tet repressor systems.
Cells infected with WR and transfected with pPL199 (Figure 6A) or
pPL201 (Figure 6B) exhibited red fluorescence at levels similar to the
transfection control, with no detectable amount of green fluorescence. This is
also true for cells infected with vS22 and transfected with pPL201 (Figure 6C).
We did find a few green fluorescent cells in wells infected with vP11IRG and
transfected with pPL199 (Figure 6D), however these were at levels
indistinguishable from the vP11IRG control (Figure 6E), and this was not
detected in cells infected with WR (Figure 6A), suggesting that this is more likely
a result of vP11IRG mutation than Bxb1 activity. Taken together, these results
support the conclusion that PhiC31 can function in VACV synthetic circuitry but is
irrepressible by the tet operon, and that our Bxb1 is not functional in our VACV
synthetic circuitry.
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DISCUSSION
The implementation of reliable invertase-based logic gates or more
complex logical circuitry in VACV vectors could greatly enhance their usefulness
in both research and medicine. Eventually, VACVs could be engineered in which
recombinases are inducible by well-studied cellular signals or transcription
factors, either host-derived or exogenous genes carried by the virus. In oncolytic
viral therapy, for example, important tumor suppressors such as p53 (59) or one
of its downstream effectors could be considered an indicator of non-cancerous
cells and accordingly used as an inducer of a recombinase that alters VACV
circuitry in such a way that inhibits VACV replication. The reverse could be done
with known oncogenes. Such an oncolytic VACV therapy would have to be
specifically designed for a particular type of tumor. Such vectors could also
include control switches allowing them to be induced or repressed within patients
with drugs. Inducible (60) and repressible (Jasperse, O’Connell, Titong, Verardi,
unpublished data) systems have already been shown to be efficacious in
controlling VACV gene expression in vivo. Similarly, VACVs could be engineered
to shut off essential gene expression in response to an adverse reaction. For
example, patients with atopic dermatitis are susceptible to developing eczema
vaccinatum. During this reaction a number of cytokines are produced, such as IL3, IL-4, and IL-5, which do not normally play a role in controlling VACV infection
(61). The cellular signaling pathways triggered by these interleukins could be
used as regulators of recombinase expression to develop a responsive logicgate.
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In these preliminary tests we were not able to demonstrate effective
recombinase-based logical circuitry in VACV vectors. In all of our experiments
wherein VACV-infected cells were transfected with our plasmids containing bxb1
(pPL199, Figure 2D and pPL201, Figure 2F), we did not detect any green
fluorescence, indicating a lack of Bxb1 activity in our VACV synthetic circuitry
(Figures 3, 5). This may be for a number of reasons. While PhiC31 has been well
characterized in eukaryotes (53), to our knowledge Bxb1 has not, and neither of
them have previously been studied in cytoplasmic DNA viruses, so the protein
product may be different than in prokaryotic cells. Even if the post-transcriptional
and post-translational modifications are correct in VACV-infected cells, bxb1 may
require codon optimization to be sufficiently expressed by VACV, however this is
less likely due to the enzymatic nature of recombinases. It is also possible that a
mutation occurred during our PCR cloning of bxb1, so there may be reason to
repeat the cloning and reattempt this assay. However, since there are numerous
other tools for altering DNA including other recombinases, transposases, and
CRISPR-Cas systems (62) which could be used in logical VACV genetic circuitry
(63), the need to invest significant resources beyond this in functionally
expressing the bxb1 transgene is limited.
In all of our assays wherein VACV-infected cells were transfected with our
plasmids containing phiC31 (pPL198, Figure 2C and pPL200, Figure 2E), both
with and without inducer, we did not detect any red fluorescence but we did
observe green fluorescence similar to the levels of the transfection control
(Figure 3, 6). This suggests that our PhiC31-based circuitry poses the opposite
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problem as it appears that the recombinase was active in every transfected cell
regardless of the repressor system and absence of inducer. It is also possible
that somehow the recombinase was expressed during cloning, prior to our
transient expression assay, inverting the target promoter and causing all of our
cells transfected with plasmids pPL198 and pPL200 to express green
irresponsive to PhiC31 expression. This direction of the promoter in the final
transfer vector will need to be verified by sequencing, possibly in conjunction with
the parental vector pPL196 for comparison. If this is the case, then measures will
be necessary to inhibit expression of this gene during cloning, even though it is
downstream of a VACV promoter, not a bacterial one.
These results present the need for new controls to better verify that
promoter inversion has occurred within the infection/transfection assay. Now that
we know the fluorescence reporter genes on these plasmids work, in future
experiments one could use the parental vectors, which lack recombinase genes,
as negative controls to verify that red fluorescent reporter is expressed in the
absence of recombinase. These or another DsRed plasmid should also be used
as a control for comparison of DsRed expression during imaging. Finally, the
best method to demonstrate promoter inversion would be to sequence the
plasmid before the infection/transfection assay, and then collect, PCR, and
sequence the plasmid DNA from wells in which green fluorescence was detected
to compare the sequences and confirm inversion.
The possibility that PhiC31 is highly active in VACV-infected cells also
warrants discussion. In this study we used the lac and tet repressors because
19

they had been thoroughly characterized previously in recombinant VACVs.
However, these systems are prone to “leaky” expression, and since even one
molecule of recombinase is theoretically sufficient to permanently alter the target
sequence, a tighter method of gene regulation may be necessary. One possibility
may simply be to decrease the strength of the promoter upstream of the
recombinase. Moss et al. characterized the strength of many natural VACV
promoters (64) and our lab recently developed a series of weakened P 11
promoters (by systematically deviating from the consensus sequence) including
the “P5” we used in pPL198-pPL201. Perhaps using an even weaker promoter
may increase repressibility of recombinase expression.
Based on the uncontrolled high efficiency of inversion exhibited by phiC31
transfected cells, it may be more practical to implement a system which better
inhibits gene expression, rather than being less capable of gene expression.
Many genetic engineers control recombinases expression using “riboregulators”.
Riboregulators are microRNAs (miRNAs) that post-transcriptionally repress the
expression of a transgene that has been tagged with a 5’-complimentary
sequence, allowing the miRNA to anneal to the transcript and form a secondary
structure blocking the ribosomal binding domain (RBD) and preventing
translation (65). Isaacs et al. originally developed both cis-repressor and transactivator systems using these molecules, and they have since been
demonstrated to have great utility as regulators in genetic switchboards (66, 67).
Characterization of these riboregulators in VACV synthetic circuitry may be an
important next step in the development of recombinase-based VACV vectors, as
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well as useful for gene regulation in VACV vectors in general. Ultimately, in
order to produce recombinant VACVs containing this sort of logical circuitry, we
will face another hurdle in making sure that no undesired recombinase
expression and activity occur during purification and amplification, further
increasing the need for a much stricter mechanism for control of gene
expression.
We believe that we have developed a transient expression system for
testing the functionality of recombinases and corresponding regulators of gene
expression in VACV. Although we did not succeed in demonstrating induciblerecombinase logic in VACV vectors, we did elucidate the problems that must be
overcome in order to successfully develop this technology. Establishment of just
two recombinases functional in VACV synthetic circuitry as well as an adequate
regulatory system for the expression of these genes would allow for the
implementation of binary logic gates in VACV vectors with tremendous potential
for medical and research applications.
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Figures

Figure 1. Recombinase test vector concept. To test the functionality and
repressibility of recombinases in VACV synthetic circuitry, we developed constructs that
constitutively express a repressor (TetR or LacI, here “Rep”), which in the absence of
the inducer binds to an operator, blocking transcription of the recombinase. In the
presence of inducer (yellow squares), a conformational change occurs in the repressor
protein, releasing it from the operator, permitting transcription of the recombinase. This
catalyzes the inversion of a promoter, switching fluorescence reporter expression from
red to green.
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Figure 2. Recombinase test plasmid maps. Plasmid vector backbones pPL189
(A) and pPL190 (B) were synthesized by DNA 2.0 with a high-copy E. coli origin
of replication and kanamycin resistance gene. EGFP, DsRed, repressors, and
recombinases were cloned into backbones to produce recombinase test
plasmids pPL198 (C) pPL199 (D) pPL200 (E) and pPL201 (F) for use in transient
expression assays.
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Figure 3. Initial test of logical circuits transient expression assay.
Representative images of our pilot transient expression assay. BS-C-1 cells were
infected with WR at an MOI of 1 and after 1 hour overlaid with complete DME
supplemented with 2.5% FBS, with or without 1mg/ml doxycycline or 1mM IPTG
and transfected with pPL198, pPL199. Wells were imaged using FITC (Green)
and Texas Red (Red) fluorescent filters, and brightfield (BF) after 24 (A) and 48
(B) hours p.t. As a transfection control, an uninfected monolayer was transfected
with a plasmid coding for EGFP under a constitutive CMV promoter (C).
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Figure 4. Repressibility of EGFP expression in vP11IRG-infected HeLa-S3
cells. HeLa-S3 cells were infected with vP11IRG at an MOI of 1 and overlaid
with 1 mg/ml Dox. Wells were imaged using FITC (Green) and Texas Red (Red)
fluorescent filters, and brightfield (BF) after 24 (A), 48 (B), 72 (C) and 96 (D)
hours p.t.
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Figure 5. Expression of PhiC31 under Tet and Lac repressor systems.
HeLa-S3 cells were infected with WR for 24 hours, overlaid with or without
1mg/ml Dox or 1mM IPTG and transfected with pPL198 (A) and pPL200 (B). In
order to pre-express TetR or LacI in transfected cells, we repeated this assay
using cells infected with vS22 for pPL198 (C) and vP11IRG for pPL200 (D).
Images shown are representative of 72 hours p.t. and taken using brightfield
(BF), FITC (Green), or Texas Red (Red) fluorescent filters.
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Figure 6. Expression of Bxb1 under Tet and Lac repressor systems.
HeLa-S3 cells were infected with WR for 24 hours, overlaid with or without
1mg/ml Dox or 1mM IPTG and transfected with pPL199 (A) and pPL200 (B). In
order to pre-express TetR or LacI in transfected cells, we repeated this assay
using cells infected with vS22 for pPL200 (C) and vP11IRG for pPL199 (D).
Images shown are representative of 72 hours p.t. and taken using brightfield
(BF), FITC (Green), or Texas Red (Red) fluorescent filters.
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